Best Grants for HIV / AIDS in New Jersey

Focused on HIV/AIDS care, the New Jersey Department of Health invites New Jersey health and social service providers to support comprehensive, family-centered medical care. Eligible programs can deliver culturally competent treatment and coordinated services for infants, children, youth, women, and families affected by HIV/AIDS, with awards up to US $2,969,085 for integrated medical and ancillary support.

Nonprofit housing and HIV service providers in New Jersey can apply for the State of New Jersey Department of Health’s SSUS Housing Opportunities for Persons With AIDS program, which funds long-term housing assistance and supportive services. Grants support tenant-based rental assistance and security deposit help for low-income individuals living with HIV to improve stability and health outcomes.

Grants from the State of New Jersey Department of Health help New Jersey public health agencies and 501(c)(3) nonprofits fund STD investigation, testing, and treatment services, including integrated HIV care. Eligible municipal and county governments and nonprofits can request up to US $1,852,456 for DIS staff, expanded clinic hours, safety-net testing, and STD/HIV service integration.

New Jersey HIV / AIDS service providers can access funding to develop and implement comprehensive, status-neutral HIV services for focus populations. Programs may address specific stages or the full continuum of HIV testing, prevention, and care/treatment, emphasizing customer-centered, culturally aware, and trauma-informed interventions through the State of New Jersey Department of Health.

Eligible organizations previously funded under DHSTS Opioid 2026 or DHSTS Opioid Expansion 2026 in New Jersey can apply for State of New Jersey Department of Health support to expand harm reduction services. Funding supports HIV/STD-related harm reduction, overdose prevention, health services, and capital planning at syringe access sites, harm reduction centers, and county health departments.

The W. W. Smith Charitable Trust provides funding for basic medical research focusing on heart disease, cancer, and AIDS. Grants are available to 501(c)(3) nonprofit organizations located in the Greater Philadelphia area and Camden, NJ. Each grant typically ranges from $100,000 to $125,000 for a one-year term. The Trust aims to support unique and promising research projects that can lead to larger awards, ensuring a direct impact on health outcomes.

New Jersey HIV/AIDS research institutions and investigators can access funding through the National Institutes of Health to study how HIV immunotherapies affect central nervous system outcomes. This R21/R33 opportunity supports biphasic projects examining mechanisms, benefits, and risks in the CNS compartment, aiming to improve long-term neurologic and cognitive outcomes in people with HIV, with awards up to US $2,000,000.

New Jersey HIV/AIDS clinical research institutions can access funding through the National Institutes of Health to serve as Clinical Trials Units in HIV and HIV-associated disease studies. These units support randomized controlled trials and implementation research, operating administrative hubs and domestic or international clinical research sites within NIAID’s HIV/AIDS Clinical Trials Networks.

Research institutions and clinical trial organizations working on HIV/AIDS prevention, treatment, and implementation science, including those in New Jersey, can apply for clinical trials network Statistical and Data Management Center funding from the National Institutes of Health. Awards support leadership in trial design, data collection and monitoring, regulatory-compliant data management, and innovative statistical and data harmonization practices.

Research institutions and clinical laboratories in New Jersey working on HIV/AIDS prevention, treatment, and implementation research can access funding through the National Institutes of Health to serve as Laboratory Centers within HIV/AIDS Clinical Trials Networks. These centers provide laboratory infrastructure, testing, data management, and advanced assays to support network clinical trials and increase HIV-related testing capacity.

Nonprofit and academic research organizations working on HIV/AIDS prevention, treatment, and implementation research in New Jersey can access funding through the National Institutes of Health. US Dept. of Health & Human Services: National Institutes of Health supports four clinical trials networks to lead studies on therapeutics, biomedical prevention, immune-based strategies, and care across the lifespan.

The NIDA Core "Center of Transformative Science" Grant Program aims to enhance research on substance use, addiction, and HIV by fostering collaboration among NIH-funded researchers. Centers are expected to innovate and extend existing research through shared resources and support for new investigators. This initiative encourages interdisciplinary work and aims to transform the scientific landscape by promoting data sharing and collaborative opportunities. Applications should focus on integrating research within a specific thematic framework to maximize impact.

This funding opportunity aims to advance HIV/AIDS research by implementing human new approach methodologies (NAMs) to reduce the reliance on specific pathogen free (SPF) animal models. It emphasizes the integration of NAMs-enabled frameworks for in vitro testing while supporting essential SPF colony resources. The initiative seeks to enhance research rigor and reproducibility through innovative strategies that prioritize human-relevant models, ultimately improving HIV research outcomes and facilitating collaborative development in the field.

The National Institute of Mental Health is inviting research applications for the AIDS Research Center program, which includes Developmental Centers and full Research Centers. This initiative aims to enhance interdisciplinary HIV/AIDS research through collaboration and innovative approaches across various scientific domains. The program emphasizes alignment with national strategies and encourages applications from teams skilled in fostering partnerships with diverse stakeholders. Although applications are currently not being solicited, this notice allows potential applicants time to prepare strong proposals.

The Ryan White HIV/AIDS Program (RWHAP) Integrated HIV/AIDS Planning Resource Allocation Cooperative Agreement aims to enhance the effectiveness of HIV prevention and care planning for RWHAP Parts A and B recipients. Through the provision of training, tools, and technical assistance, this initiative seeks to optimize resource allocation and strengthen the overall system of HIV care and treatment, ultimately improving health outcomes for those affected by HIV.

The AIDS Drug Assistance Program (ADAP) Emergency Relief Funds aim to provide essential funding to states and territories. This initiative focuses on preventing, reducing, or eliminating waiting lists for ADAP services, ensuring timely access to necessary medications and support for individuals living with HIV/AIDS. This program addresses critical funding shortfalls, enhancing the healthcare infrastructure and improving health outcomes in affected communities.

The Ryan White HIV/AIDS Program Part C Capacity Development Program aims to enhance the capabilities of community-based organizations, focusing on improving health outcomes and decreasing HIV transmission. This initiative supports individuals who have not yet accessed regular HIV care, emphasizing innovative care solutions and infrastructure development to address these critical needs.

The HIV Care Grant Program, funded by the US HHS: Health Resources & Services Administration (HRSA), aims to enhance access to high-quality HIV care and treatment for low-income individuals. This initiative supports states and territories in developing comprehensive systems to address the needs of those living with HIV. By providing essential resources, the program seeks to improve health outcomes and ensure that vulnerable populations receive the necessary support and services.

The Ryan White HIV/AIDS Program Part B Supplemental Grant aims to provide essential funding to support HIV care and treatment services across states and territories. This program supplements existing formula-based funding from the RWHAP Part B and ADAP, improving access to necessary resources for those affected by HIV/AIDS. By enhancing support structures, it addresses critical healthcare needs, ensuring better health outcomes for vulnerable populations.

The HIV Care Grant Program aims to enhance access to comprehensive, high-quality HIV care and treatment for low-income individuals in Pacific Island territories. Funded by the US HHS: Health Resources & Services Administration (HRSA), this initiative supports states and territories in developing effective systems of care, ensuring that those affected by HIV receive the necessary treatment and support to improve health outcomes.

This funding opportunity aims to enhance a web-based ordering portal for distributing 1.5 million HIV and STI self-tests to high-burden communities. By optimizing access to these self-tests, the initiative seeks to raise awareness, prevent new infections, and improve the health outcomes of users, thereby contributing to better overall public health and wellbeing.

This project aims to enhance health outcomes for women living with HIV in the South by integrating HIV care with comprehensive women's health services through coordinated Clinic and Community Collaboratives. By funding organizations to implement targeted strategies such as culturally responsive services and learning collaboratives, the initiative seeks to improve access to essential health services, increase the number of women initiating rapid ART, and foster sustainable healthcare models that address the unique needs of this population.

The Ryan White HIV/AIDS Program Part D provides supplemental funding aimed at enhancing the infrastructure and capacity of organizations to deliver high-quality, family-centered HIV care services. This initiative focuses on two key areas: HIV Care Innovation and Infrastructure Development, ensuring improved access to essential services for women, infants, children, and youth affected by HIV.

The Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Training and Technical Assistance aims to enhance the capacity of ADAPs. By providing essential tools and expert guidance, the program seeks to improve health outcomes for individuals living with HIV in an evolving healthcare landscape. This initiative is funded by the US HHS through the Health Resources & Services Administration, ensuring support and resources are effectively allocated to meet the needs of vulnerable populations.

Gilead Sciences

At Gilead, we are relentlessly committed to advancing transformative therapies for the most serious diseases, delivering an exponentially positive impact on health.

For more than three decades, we have combined scientific rigor with a deep sense of purpose to improve health outcomes and reimagine care. Our work spans more than 35 countries with a focus on three therapeutic areas: virology, oncology, and inflammation, where unmet medical needs remain greatest.

From individual patients to whole populations, we’re committed to delivering healthier futures for people and communities worldwide.

Our Mission: To discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

HIV Prevention NOVA 2026

Program Description

Gilead Sciences invites research proposals that advance the evidence base for innovative and scalable models of delivery for long-acting (LA) HIV pre-exposure prophylaxis (PrEP) in the United States.

This Topic of Interest (TOI) is focused on care delivery models implemented in non-traditional settings, defined as clinical and non-clinical environments where PrEP services are not routinely provided. Emphasis is placed on approaches that reflect real-life practice and address gaps in current PrEP delivery infrastructure.

Persistent inequities in PrEP uptake in the U.S. suggest that expanding availability within traditional clinical settings alone is unlikely to reach all populations with unmet PrEP need.1,2 Rigorous implementation studies in non-traditional settings where PrEP services are not routinely provided are needed to evaluate whether these models can reduce access barriers and improve equitable reach among individuals who may benefit from PrEP.2,3,4

The goal of this TOI is to generate practical, decision-relevant evidence that informs how LA PrEP can be implemented, scaled, and sustained in real-life U.S. settings.

About Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Who we are and our impact

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

HIV, AIDS, and prevention

Help with healthcare costs for HIV, AIDS, and prevention

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

About the disease

HIV, also known as human immunodeficiency virus or acquired immunodeficiency syndrome, is a virus that attacks the immune system. When left untreated, it can develop into AIDS. HIV is a chronic disease that affects the immune system.

The SCORCH Program: Phase 2 aims to enhance the understanding of single cell biology in the context of HIV and Substance Use Disorder (SUD). Building on previous research, this initiative will explore new single cell approaches to investigate the interactions between SUD and HIV progression at various biological levels. By leveraging advanced techniques, the program seeks to identify candidate mechanisms and potential therapeutic targets, ultimately contributing to innovative solutions for SUDs and HIV-related challenges.